Q3 2024 BioArctic AB Earnings Call(Q&A-session) Transcript
Key Points
- BioArctic AB (BRCTF) reported a significant increase in royalties from Leqembi sales, with over 60% growth compared to the previous quarter.
- The company's BrainTransporter technology is progressing well, with promising preclinical data showing enhanced brain distribution in both transgenic mice and nonhuman primates.
- BioArctic AB (BRCTF) maintains a solid financial position, with SEK 804 million in cash and short-term investments, allowing continued focus on project development.
- The company's pipeline is advancing, with the initiation of Phase 2A studies for Parkinson's disease and plans to start dosing soon.
- Leqembi has been approved and launched in multiple countries, including the US, Japan, and China, with sales exceeding expectations in Japan and China.
- BioArctic AB (BRCTF) experienced a decrease in net revenues compared to the previous year, primarily due to the absence of milestone payments.
- The company faces challenges with infusion capacity for Leqembi in the US, which has limited sales growth despite high demand.
- Operating expenses have increased, particularly in R&D, which is expected to continue rising as project development progresses.
- There is uncertainty regarding the approval of Leqembi in the EU, with the outcome of the CHMP opinion still pending.
- BioArctic AB (BRCTF) has not yet achieved profitability, although growing royalties are starting to offset R&D expenses.
Welcome to BioArctic Q3 report 2024.
(Operator instructions).
I will hand the conference over to CEO Gunilla Osswald and CFO Anders Martin-Löf. Please go ahead.
Good morning and welcome to BioArctic presentation for the third quarter of 2024.
I have three key messages for today. The first one is that our projects are progressing very well, and I'm really excited about our BrainTransporter technology, where we now have been presenting data publicly and I will show some of those data here today. Our project for Parkinson's disease has initiated Phase two A with screening of patients. My second message is that Leqembi sales are increasing, resulting in over 60% higher royalties for us, compared to previous quarter. The market in the US continues to grow and Japan and China are above expectations, and the regulatory process continues, and we are eagerly awaiting CHMP opinion tomorrow. The third message is that we have a solid financial situation so we can focus on progressing our projects in a good way.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
